DEERFIELD, Ill., May 28, 2014 - Baxter International Inc. (NYSE:BAX) continues to build upon its global leadership position in hemophilia with ADVATE [Antihemophilic Factor (Recombinant)], the first recombinant treatment with no human or animal protein additives for patients with hemophilia A. ADVATE continues to be the most prescribed full-length recombinant FVIII worldwide, with more than 10 years of real-world experience and over 17 billion units distributed.
Baxter U.S. - Baxter Builds on Global Leadership in Hemophilia A
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.